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Background
T cells from patients with chronic lymphocytic leukemia may play an important role in con-
tributing to the onset, sustenance, and exacerbation of the disease by providing survival and
proliferative signals to the leukemic clone within lymph nodes and bone marrow. 
Design and Methods
By performing chemotaxis assays towards CXCL12, CCL21 and CCL19, we sought to evalu-
ate the migratory potential of T cells from chronic lymphocytic leukemia patients. We next
analyzed the chemokine-induced migration of T cells, dividing the chronic lymphocytic
leukemia samples according to their expression of the poor prognostic factors CD38 and ZAP-
70 in leukemic cells determined by flow cytometry.
Results
We found that T cells from patients with chronic lymphocytic leukemia are less responsive to
CXCL12, CCL21 and CCL19 than T cells from healthy adults despite similar CXCR4 and
CCR7 expression. Following separation of the patients into two groups according to ZAP-70
expression, we found that T cells from ZAP-70-negative samples showed significantly less
migration towards CXCL12 compared to T cells from ZAP-70-positive samples and that this
was not due to defective CXCR4 down-regulation, F-actin polymerization or to a lesser expres-
sion of ZAP-70, CD3, CD45, CD38 or CXCR7 on these cells. Interestingly, we found that
leukemic cells from ZAP-70-negative samples seem to be responsible for the defective CXCR4
migratory response observed in their T cells.  
Conclusions
Impaired migration towards CXCL12 may reduce the access of T cells from ZAP-70-negative
patients to lymphoid organs, creating a less favorable microenvironment for leukemic cell sur-
vival and proliferation.
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B-cell chronic lymphocytic leukemia (CLL) is character-
ized by a lymphocytosis of small mature clonal CD5+ B
lymphocytes in blood, peripheral lymphoid organs and
bone marrow. The clinical course of CLL is very heteroge-
neous and a number of prognostic factors may help to pre-
dict the outcome of the disease. Thus, patients with poor
prognosis, who develop aggressive disease requiring early
therapy, typically display leukemic cells with B-cell recep-
tors encoded by unmutated immunoglobulin variable
heavy-chain genes (IgVH) and express the protein tyrosine
kinase ZAP-70 and the type II transmembrane glycopro-
tein CD38.1-4 By contrast, mutated IgVH genes and the
absence of ZAP-70 and CD38 are mostly found in
leukemic cells from patients with a good prognosis, who
have a more stable, indolent disease, with no benefit from
palliative chemotherapy.5
CLL is now widely viewed as a dynamic lymphoid neo-
plasm comprising leukemic cells that multiply and die at
measurable rates.6 Although 99% of circulating malignant
B cells are in the G0/G1 phase of the cell cycle, clusters of
larger leukemic cells can be found in lymph nodes and
bone marrow. These clusters of CLL cells expressing cell-
cycle markers and particular anti-apoptotic molecules are
arranged in particular areas termed proliferation centers7,8
where the selected microenvironmental signals delivered
by non-leukemic cells, such as stromal and T cells, appear
to confer CLL lymphocytes with a growth advantage and
extended survival.9,10 In vitro findings suggest that T cells,
particularly CD4+CD40L+ cells, provide short-term sup-
port which influences malignant B-cell proliferation
through secretion of cytokines (e.g. interleukin-4 or inter-
feron-γ) and CD40/CD40L interactions,10-12 while stromal
cells and accessory cells provide long-term support favor-
ing prolonged survival and accumulation of leukemic
cells. 
Various studies have focused on chemokine-chemokine
receptor interactions implicated in malignant B-cell hom-
ing to lymph nodes and bone marrow.13-18 Leukemic B
cells from CLL patients express high levels of CCR7,
CXCR4 and CXCR5,14-16 which are the main chemokine
receptors that mediate B-cell entry into secondary lym-
phoid organs and their positioning in T- and B-cell zones.
Of note, ZAP-70 and CD38 expression in leukemic cells is
associated with an enhanced ability to respond through
CCR7 and CXCR4.17,18 In contrast to the well-known role
of chemokines in CLL B-cell migration, there is no infor-
mation about the ability of T cells from CLL patients to
respond to lymphoid organ chemokines. This is not a
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Figure 1. T-cell migration towards CXCL12, CCL21 and CCL19 and the expression of CXCR4 and CCR7 in T cells from healthy donors and
CLL patients. (A) PBMC from CLL patients or healthy adults were placed in the upper chamber of a 24-transwell plate; medium alone (con-
trol wells) or with the optimal dose of CXCL12 (1 mg/mL), CCL21 (1 mg/mL) or CCL19 (5 mg/mL) as chemoattractant was placed in the lower
chamber. After 2 h of culture the migrating cells were suspended and divided into aliquots for counting with a FACSCalibur or for
immunophenotyping. The migration index for each sample was calculated by determining the ratio of migrated T cells in chemokine-treat-
ed wells versus control wells, taking the spontaneous migration in control wells as 100%. NS: not significant; *P<0.01 Mann-Whitney test.
(B) Freshly collected whole blood from CLL patients or healthy donors was incubated with saturating concentrations of PerCP-conjugated
anti-CD3 antibodies and PE-conjugated anti-CXCR4 (clone 12G5) or anti-CCR7 (clone 3D12), or the appropriate isotype control antibody for
30 min at 4ºC. After selective red blood cell lysis the white cell pellet was evaluated by flow cytometry. Results are expressed as the mean
































































































trivial issue as the T-cell compartment in CLL patients
presents numerous qualitative and quantitative abnor-
malities,19-21 some of which could be directly related to its
interaction with the leukemic clone itself.22 The aim of
this study was, therefore, to evaluate the responsiveness
of T cells from good and bad prognosis CLL patients to
CXCL12, CCL21 and CCL19, the central chemokines
involved in T-cell recruitment to lymphoid organs.23-25
Design and Methods
All reagents and antibodies used, the preparation of the sam-
ples from CLL patients and healthy donors, cell separation pro-
cedures and cultures are described in detail in the Online
Supplementary Appendix. 
The expression of CD38, CD19, CD3, CD56, CD19 and ZAP-
70 was determined by flow cytometry. Patients were considered
ZAP-70+ when 20% or more of their CD19+ cells expressed ZAP-
70. CXCR4 and CCR7 surface expression on T cells from CLL
patients or healthy donors was performed by direct staining of
whole blood samples in order to avoid Ficoll purification, which
can transiently affect chemokine receptor expression, followed
by flow cytometry. 
Chemotaxis assays towards CXCL12, CCL21 and CCL19 were
conducted to evaluate the migratory potential of T cells from CLL
patients and healthy controls. The migration index was calculated
by determining the ratio of migrated CD3+CD56- (CD4+ or CD8+)
cells in chemokine-treated wells versus control wells, taking the
spontaneous migration in control wells as 100%. 
The time course and dose-dependency of CXCR4 endocytosis
in T cells from CLL patients in response to CXCL12 were exam-
ined and F-actin polymerization was evaluated. Finally, co-cul-
ture experiments were conducted in which T cells were cultured
in complete medium alone (pT cultures) or at a 1:4 ratio with
autologous pCLL (pT+pCLL cultures). Chemotaxis assays
towards CXCL12 (1 mg/mL) were performed as previously
described with freshly purified and 48 h cultured cells. In these
experiments, the relative migration of CD3+ cells was calculated
by taking the migration index of T cells in pT+pCLL cultures as
100%.
The design and methods of the study are described more
extensively in the Online Supplementary Appendix. 
Statistical analysis
For statistical comparisons between groups the non-parametric
Mann-Whitney test or one way ANOVA, Bonferroni’s multiple
comparison test was used. The significance of migration indices
was analyzed using a one sample t test or the Wilcoxon’s signed
rank test. 
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Table 1. Age, sex and main cellular characteristics of the CLL patients enrolled in the study. 
Patient % in PBL ZAP-70 CD38 T-cell migration index
ID Sex Age B cells T cells % +/- % towards CXCL12
1 F 72 77 16 0 - 51 623
2 M 70 86 12 0 - 4 1896
3 M 73 80 15 10 - 0.5 1654
4 M 68 56 14 0.2 - 0.5 694
5 M 70 88 10 1 - 1 1160
6 M 76 77 13 6 - 1 273
7 M 70 80 18 0.1 - 0.1 1458
8 M 54 67 30 0.1 - 1 1260
9 F 67 96 3 19 - 6 889
10 M 67 58 26 10 - 5 975
11 F 86 60 38 0 - 6 1395
12 M 78 87 10 2 - 3 1126
13 M 72 78 20 9 - 7 874
14 M 69 56 40 2 - 13 4532
15 M 41 74 21 12 - 41 3201
16 M 66 65 25 1 - 60 3811
17 M 45 87 12 30 + 0.5 2536
18 M 78 86 10 56 + 2 5147
19 M 66 60 26 54 + 2 3934
20 F 74 68 17 59 + 3 1400
21 F 67 56 28 36 + 7 4837
22 F 46 80 13 26 + 16 2190
23 F 65 62 31 60 + 18 1500
24 M 65 66 23 25 + 70 1379
25 F 67 86 10 66 + 87 1513
26 F 70 76 20 27 + 92 1930
27 M 68 20 60 79 + 96 3580
28 M 67 80 17 77 + 100 1900
The table shows the percentages of CD19+ cells (B cells, >99% CLL cells) and CD3+ cells (T lymphocytes) in peripheral blood lymphocytes (PBL) from each patient. A sample












T cells from chronic lymphocytic leukemia patients are
less responsive to CXCL12, CCL21 and CCL19 than 
T cells from healthy adults
In order to evaluate the capacity of T cells from CLL
patients to migrate towards CXCL12, CCL21 and
CCL19, we performed transwell chemotaxis assays. We
first determined the optimal chemokine concentration
for T cells from CLL patients and healthy adults by per-
forming dose-response chemotaxis assays (Online
Supplementary Figure S2) and chose 1 mg/mL of CXCL12,
1 mg/mL of CCL21 and 5 mg/mL of CCL19 for further
assays. The chemotactic response of T cells, expressed as
CD3+ migration index, is depicted in Figure 1A. T cells
from CLL patients were less responsive to CXCL12,
CCL21 and CCL19 than T cells from healthy donors,
with the differences being statistically significant for
CXCL12 and CCL21. The migration of CD4+ T cells and
CD8+ T cells towards the chemokines was comparable
(data not shown). As expected, treatment of the cells with
CXCL12, CCL21 or CCL19 prior to the chemotaxis assay
completely abrogated their migratory response to
CXCL12, CCL21 and CCL19, respectively (Online
Supplementary Figure S3) due to down-regulation of the
corresponding receptor. The different migration of T
cells from CLL patients and healthy adults could not be
ascribed to differences in CXCR4 and CCR7 expression
(Figure 1B). In addition, the expression of CXCR4 and
CCR7 was similar in CD4+ T cells and CD8+ T cells
(Online Supplementary Figure S4).
T cells from ZAP-70– chronic lymphocytic leukemia
patients are less responsive to CXCL12 than T cells from
ZAP-70+ patients and healthy adults
We next analyzed the chemokine-induced migration of
T cells according to whether the cells came from patients
with high or low risk CLL, defined by flow cytometrically
determined expression of the poor prognostic factors
CD38 and ZAP-70 in CLL cells. Table 1 shows the main
characteristics of the 28 CLL patients enrolled in our study,
including the percentages of CD19+ cells positive for ZAP-
70 and CD38. Although CD38 expression is undisputedly
a reliable negative prognostic marker in CLL, since there
are discrepancies in defining the cut-off for positive val-
ues,26-28 we decided to separate our CLL samples using both
the 7%27 and 30%28 cut-off values. As shown in Figure 2 A-
B, in both cases T cells from CD38– patients were less
responsive to CXCL12 and CCL19 than T cells from
CD38+ patients, although the differences were not statisti-
cally significant, while comparable responses were found
for CCL21 in CD38– and CD38+ samples. No differences in
CXCR4 and CCR7 expression in T cells were found
between CD38+ and CD38– CLL patients (Online
Supplementary Table S1). 
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Figure 2. T-cell migration towards CXCL12, CCL21 and CCL19 in CLL patients separated according to CD38 and ZAP-70 expression. The fig-
ure shows the migration indices of T cells from CLL patients divided according to CD38 expression using cut-off values of 7% (A) and 30%
(B) and according to ZAP-70 expression (C). NS: not significant, *P<0.01 Mann Whitney test. (D) Migration towards CXCL12 of T cells from
ZAP-70– and ZAP-70+ CLL patients and healthy donors. Black boxes correspond to CD38+ CLL patients and white boxes represent CD38– CLL
patients using the 7% cut-off value. T cells from ZAP-70– CLL patients had lower migration indices towards CXCL12 than T cells from ZAP-






































































































Of note, when we analyzed T-cell migration in ZAP-70+
and ZAP-70– subsets, we found that the migratory capaci-
ty towards CXCL12 was lower in ZAP-70– samples than in
ZAP-70+ samples (Figure 2C). It should be mentioned that
this difference in migratory capacity was highly significant
(P=0.009) even though the T cells from both groups of CLL
patients expressed similar surface levels of CXCR4 (Online
Supplementary Table S1). As shown in Figure 2D, when we
compared the migration indices towards CXCL12 of T
cells from healthy donors and CLL patients separated
according to ZAP-70 expression, we found, surprisingly,
that only T cells from ZAP-70– samples showed a signifi-
cantly defective migratory capacity compared to cells from
healthy donors, while no statistically significant differ-
ences were found between T cells from ZAP-70+ CLL
patients and healthy donors. In addition, when CD38+
cases were distinguished from CD38– cases within each
group, T cells from the ZAP-70-CD38– samples seemed to
have the lowest migratory capacity towards CXCL12.
Comparable migratory capacity was found between CD4+
T cells and CD8+ T cells within each group (data not shown).
CXCL12 induces similar CXCR4 endocytosis and F-actin
polymerization in T cells from ZAP-70+ and ZAP-70–
patients
Receptor internalization by endocytosis is characteristic
of chemokine receptors and may allow for continuous
sampling of chemoattractants, enabling the cells to follow
a chemotactic gradient. We, therefore, investigated
whether the different migratory capacity of T cells from
ZAP-70+ and ZAP-70– CLL patients towards CXCL12 was
due to different CXCR4 down-regulation. Figure 3A shows
the percentage of CXCR4 on T cells from healthy donors,
ZAP-70+ and ZAP-70– CLL patients after incubation for var-
ious times with CXCL12 (1 mg/mL) relative to control cells
(without CXCL12). T cells from both groups of CLL
patients and healthy donors down-regulated CXCR4 com-
parably in a time-dependent fashion after incubation with
this optimal concentration of CXCL12. In order to deter-
mine the dose-dependency of CXCR4 endocytosis, periph-
eral blood mononuclear cells (PBMC) from healthy donors
and CLL patients were incubated with increasing concen-
trations of CXCL12 or medium alone and surface CXCR4
expression was evaluated after 1 h of culture. CXCL12
induced similar dose-dependent down-modulation of
CXCR4 on T cells from each group (Figure 3B).
Reorganization of the actin cytoskeleton is an early, piv-
otal event in the migratory response to chemokines. Since
it was reported that T cells from CLL patients regulate
actin polymerization inappropriately when in contact with
antigen-presenting cells,29 we examined the ability of
CXCL12 to induce changes in the actin cytoskeleton of T
cells from healthy donors and ZAP-70+ and ZAP-70– CLL
patients by evaluating the expression of filamentous actin
(F-actin) in response to CXCL12. As shown in Figure 3C,
there were robust, transient increases in F-actin in T cells
within 5 sec after exposure to the chemokine, followed by
depolymerization in all the samples analyzed. However,
CXCL12 induced significantly less F-actin polymerization
in T cells from CLL patients than in T cells from healthy
donors; there were no differences between the two CLL
groups.
The impaired migratory capacity of T cells from ZAP-70–
patients was not related to lower expression of ZAP-70,
CD3, CD38, CD45 or CXCR7 on these cells 
It was previously reported that ZAP-70, a key element in
T-cell receptor (TCR) signaling, is required for CXCR4 sig-
nal transduction.30,31 However, when we compared the
expression of ZAP-70 within T cells from ZAP-70– and
ZAP-70+ CLL samples we found no differences between
groups (Online Supplementary Figure S5A) indicating that a
dissimilar expression of ZAP-70 in T cells could not explain
M. Borge et al.
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Figure 3. The impaired migratory capacity of T cells from ZAP-70–
CLL patients was not related to defective CXCR4 down-regulation or
a particular actin polymerization defect. (A) PBMC from six ZAP-70–
(dotted line), six ZAP-70+ CLL patients (dashed line) and six healthy
donors (solid line) were incubated with medium alone (control) or
with CXCL12 (1 mg/mL) at 37ºC for 0, 2, 5, 15 and 60 min and the
remaining CXCR4 on CD3+ cells was assessed by flow cytometry.
The graph shows the percentage of CXCR4 on the surface of CD3+
cells treated with CXCL12 relative to the control. (B) PBMC from
ZAP-70– and ZAP-70+ CLL patients and healthy donors were incubat-
ed for 60 min with different concentrations of CXCL12 (0, 10, 100,
1000 ng/mL) at 37ºC. The expression of remaining CXCR4 on the
surface of T cells was then analyzed by flow cytometry. The data
shown represent the mean±SEM (n=6) for the percentage of CXCR4
expression on the surface of CXCL12-treated T cells relative to con-
trol T cells (medium alone). (C) Intracellular F-actin was measured
using FITC-labeled phalloidin in purified T cells from three ZAP-70–
CLL patients, three ZAP-70+ CLL patients and three healthy donors
after the addition of CXCL12 (1000 ng/mL) for 15, 30 and 300 sec.
Results are shown as the mean±SEM of the percent of intracellular
F-actin relative to the value before the addition of CXCL12. *P<0.05
Mann-Whitney test (CLL versus healthy donors).
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the different migratory capacity towards CXCL12 found in
ZAP-70– and ZAP-70+ samples.
Since it was reported that CXCL12 stimulates the phys-
ical association of CXCR4 and TCR/CD3 and utilizes the
ZAP-70 binding ITAM domains of the CD3 for signal
transduction,32 we evaluated CD3 expression in PBMC
from both groups of CLL patients without finding any sig-
nificant difference in its expression (Online Supplementary
Figure S5B). In addition, when we evaluated the expression
of two other molecules which could influence T-cell
chemotaxis towards CXCL12, the ectoenzyme CD38 and
the tyrosine phosphatase CD45 (Online Supplementary
Figure S5 C and D)33,34 we found comparable levels of
expression in T cells from ZAP-70– and ZAP-70+ CLL sam-
ples. Finally, we evaluated the expression of CXCR7, a
recently identified receptor for the chemokine CXCL12
which might influence CXCR4-mediated T-cell chemo-
taxis35 and found no differences in surface or intracellular
CXCR7 expression between groups (Online Supplementary
Figure S5E). Collectively, these results indicate that the
lower migratory response towards CXCL12 found in T
cells from ZAP-70– samples could not be ascribed to lesser
expression of ZAP-70, CD3, CD45, CD38 or CXCR7 mol-
ecules on these cells.
Leukemic cells from ZAP-70– patients, but not from ZAP-
70+ samples, reduce T-cell migration towards CXCL12
Since it was previously reported that the presence of
leukemic CLL cells induces specific changes in T cells
resulting in functional impairment,22,29 we evaluated
whether CLL cells from ZAP-70– and ZAP-70+ samples can
modulate autologous T-cell responses towards CXCL12.
To this aim, purified T cells were cultured alone or with
autologous CLL cells (ratio T cells: CLL cells = 1:4). T-cell
chemotaxis towards CXCL12 was evaluated with freshly
purified cells and cells cultured for 48 h. As shown in Figure
4A, comparable migratory capacity towards CXCL12 was
found between freshly purified T cells alone (pT) or with
autologous CLL cells (pT+pCLL) in both ZAP-70– and ZAP-
70+ samples. Similar results were obtained with T cells
from ZAP-70+ patients after 48 h of culture (Figure 4B). By
contrast, in all of the ZAP-70– patients evaluated, purified T
cells cultured for 48 h alone (pT) showed greater migrato-
ry capacity towards CXCL12 compared to purified T cells
cultured with autologous CLL cells (pT+pCLL) (Figure 4B),
although CXCR4 surface expression was similar in both
groups (Online Supplementary Figure S6).
Discussion
During the past few years, it has increasingly been rec-
ognized that signals from the microenvironment make piv-
otal contributions to the progression of CLL. T lympho-
cytes and stromal cells appear to be essential players,36
interacting with leukemic cells in anatomical structures
called proliferation centers. Since there was no information
about the ability of T cells from CLL patients to respond to
lymphoid organ chemokines, we evaluated the migratory
potential of T cells from high risk and low risk CLL
patients by performing chemotaxis assays towards
CXCL12, CCL21 and CCL19 in CLL samples and in
healthy donors. 
When CLL patients as a whole group were compared
with healthy donors, we found that T cells from the CLL
patients responded to CXCL12, CCL21 and CCL19, albeit
less well than T cells from their healthy counterparts. Since
CCR7 and its ligands are essentially involved in T-cell and
dendritic-cell homing to the lymph nodes, where T cells
establish close physical contacts with dendritic cells to
allow their antigen-specific activation, the lower CCR7-
induced chemotaxis of T cells from CLL patients might
contribute to their impaired cell-mediated immunity.37
We found similar CXCR4 and CCR7 expression in T
cells from CLL patients and healthy donors, confirming a
previous report of comparable CCR7 expression in T cells
from normal subjects and CLL patients.38 Regarding
CXCR4 expression, our results differ from those of
Kratchard et al.who reported a higher expression in T cells
from CLL patients.39 This discrepancy may be due to differ-
ent experimental conditions used, since we directly stained
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Figure 4. CLL cells from ZAP-70– patients reduce T-cell migration
towards CXCL12. Purified T cells from ZAP-70– (n= 10) and ZAP-70+
CLL patients (n=9) were cultured in complete medium alone (pT cul-
tures) or at a 1:4 ratio with autologous purified CLL cells (pT+pCLL
cultures). Chemotaxis assays towards CXCL12 (1 mg/mL) were per-
formed with freshly purified cells (A) and 48 h cultured cells (B). The
migration of CD3+ cells was calculated by taking the migration index
of T cells in pT+pCLL cultures as 100%. Bars represent the mean
values±SEM for the CD3+ migration. NS: not significant, *P=0.001,
Wilcoxon’s signed rank test. The lower panels show the migration
indices of pT+pCLL and pT from 48 h cultured cells of each patient,
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whole blood samples while Kratchard et al. evaluated
CXCR4 expression after isolation of mononuclear leuko-
cytes from peripheral blood by Ficoll-Hypaque centrifuga-
tion. Despite having similar CXCR4 and CCR7 expression,
T cells from CLL patients consistently showed a lower
migratory capacity towards their ligands compared to
healthy T cells. Other studies have already shown that
chemokine responsiveness does not correlate with
chemokine receptor expression levels. Concerning
CXCR4, it was reported that its expression in bone mar-
row B cells and the migratory response towards CXCL12
was not associated at all.40 In addition, it was observed that
B cells become highly responsive to the chemokine CCL20
after cellular activation without changes in the expression
of its receptor41 and also that mature dendritic cells express
the homing receptor CCR7 but migrate poorly in response
to CCL19 and CCL21 without prior exposure to
prostaglandin E2.42
When CLL patients were divided according to ZAP-70
expression, we found, surprisingly, that the lower migra-
tion towards CXCL12 is a distinctive feature of T cells
from ZAP-70– CLL patients. The combination of ZAP-70
and CD38 appears to be more useful than either ZAP-70
or CD38 alone in identifying patients with a worse (ZAP-
70+CD38+) or better (ZAP-70–CD38–) prognosis.1,2,4 In our
samples, when ZAP-70– and ZAP-70+ CLL patients were
further separated according to CD38 expression, we
found that only T cells from ZAP-70–CD38– CLL samples
had a significantly reduced migratory capacity towards
CXCL12 compared to healthy T cells, although more CLL
samples must be analyzed to allow firm conclusions to be
drawn. Interestingly, Roth et al. recently reported that the
average telomere loss was higher for T cells in ZAP-
70+CD38+ CLL patients than in ZAP-70–CD38– ones indi-
cating an extensive expansion within the T-cell compart-
ment in the former group of CLL patients.43 Altogether,
our results and the observations made by Roth indicate
that accessory T cells from ZAP-70+ and ZAP-70– patients
are different. 
Given that CXCL12-induced migration seems to be reg-
ulated by intricate mechanisms besides CXCR4 expres-
sion, we further investigated other molecules and mecha-
nisms capable of regulating CXCL12 responsiveness of T
cells from CLL patients. Since it was previously reported
that ZAP-70, CD38 and CD45 expression was associated
with an enhanced response through CXCR4,33,34 we evalu-
ated their expression in T cells from CLL patients without
finding any significant difference between ZAP-70+ and
ZAP-70– groups. Likewise, expression of CXCR7, a recent-
ly identified receptor for the chemokine CXCL12, was
comparable in T cells from both groups. The lower migra-
tory response of T cells from ZAP-70– CLL patients could
not be ascribed to a deficiency in receptor endocytosis
upon CXCL12 treatment, since T cells from both groups of
CLL patients and healthy donors comparably down-regu-
lated CXCR4 in a time- and dose-dependent fashion.
Finally, as previously described by Gribben et al. for
synapse formation29 we observed an F-actin polymeriza-
tion defect upon CXCL12 stimulation in T cells from CLL
patients compared to normal T cells, but no significant dif-
ferences between the two groups of CLL patients, indicat-
ing that actin polymerization could not explain the differ-
ent migratory capacity observed between T cells from
ZAP-70– and ZAP-70+ CLL samples.
A number of reports suggested that CLL cells are not pas-
sive players, but that they actively modify their own
microenvironment: for example, they have the capacity to
attract accessory cells within lymphatic tissues,13,44,45 and
can induce specific changes in T cells22 which can alter T-
cell immunological recognition and function.29 We, there-
fore, investigated whether the leukemic clone itself was
involved in the reduced migratory capacity towards
CXCL12 displayed by T cells from the ZAP-70– group. We
found that purified T cells from ZAP-70–, and not from
ZAP-70+ patients, cultured alone for 48 h showed a signifi-
cantly greater capacity to migrate towards CXCL12 com-
pared to T cells cultured with autologous CLL cells, sug-
gesting that T-cell migratory responses to CXCL12 are
strongly affected by leukemic cells in ZAP-70– patients but
not in ZAP-70+ samples. It remains to be determined which
processes involved in CXCL12-induced migration of T
cells are affected by ZAP-70– CLL cells.
Since T cells in proliferation centers may help CLL cells
to survive and proliferate, the low migratory response
towards CXCL12 in T cells from ZAP-70– CLL patients
might favor the indolent clinical course of the disease in
these patients. Experiments evaluating the quantity and
functional quality of the T-cell compartment from ZAP-70+
and ZAP-70– CLL lymphoid organs are warranted.
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